Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 10:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1489–1512 of 2,669 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control II Clear all
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Multiple Doses of LT3001 Drug Product in AIS Subjects

NCT05403866
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
LT3001 Drug Product, Placebo
Drug
Lead sponsor
Lumosa Therapeutics Co., Ltd.
Industry
Eligibility
18 Years to 90 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Oct 31, 2026, 10:14 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Efficacy of mHealth Apps for Health in a Low-income, Type II Diabetic, Hispanic Population

NCT05279729
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Obesity
Interventions
Mobile health application
Other
Lead sponsor
San Diego State University
Other
Eligibility
18 Years to 64 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 31, 2026, 10:14 PM EDT
Withdrawn Phase 3 Interventional

Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma

NCT00551239
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
rituximab, fludarabine phosphate, pixantrone dimaleate
Biological · Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 31, 2026, 10:14 PM EDT
Withdrawn Phase 2 Interventional

RBD-HPV: Risk-Based De-Intensification for HPV+ HNSCC

NCT04849377
View directory record Official record
Conditions
Human Papillomavirus (HPV), Head and Neck Squamous Cell Carcinoma (HNSCC)
Interventions
RT 50 Gy, RT 54 GY, RT 60 GY, Induction Therapy, Carboplatin, Cisplatin 200, Cisplatin 240
Radiation · Other · Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 7, 2022 · Synced Oct 31, 2026, 10:14 PM EDT
Completed Phase 2Phase 3 Interventional

Does BRV Have Faster Onset Time & Greater Effect Than LEV in Epilepsy Pts Using PPR Pharmacodynamic Efficacy Endpoint

NCT03580707
View directory record Official record
Conditions
Photosensitive Epilepsy
Interventions
BRV vs LEV in randomized double blinded, crossover fashion
Drug
Lead sponsor
Rosenfeld, William E., M.D.
Individual
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Oct 31, 2026, 10:14 PM EDT
Completed Phase 2 Interventional Results available

A Phase II, Cross-over Clinical Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) in the On-demand Treatment of Angioedema Attacks in Adult Subjects With Hereditary Angioedema Type I or II

NCT04208412
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
KVD900, Placebo
Drug · Other
Lead sponsor
KalVista Pharmaceuticals, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
Scottsdale, Arizona • Centennial, Colorado • Chevy Chase, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated May 2, 2025 · Synced Oct 31, 2026, 10:14 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety, Tolerability and Immune Response to LC002, an Experimental Therapeutic Vaccine, in Adults Receiving HAART

NCT00270205
View directory record Official record
Conditions
HIV Infections
Interventions
LC002 standard vaccination, LC002 high-dose vaccination, LC002 placebo vaccination
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
5
States / cities
Sacramento, California • Chicago, Illinois • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 31, 2026, 10:14 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Suubi4PrEP: Improving PrEP Access and Adherence Among Adolescent Girls and Young Women in Uganda

NCT07002866
View directory record Official record
Conditions
HIV Prevention
Interventions
HIV Risk Reduction (HIVRR), PrEP Peer Supporters (PS), Matched Savings Accounts + Financial Literacy (FL)
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
15 Years to 24 Years · Female only
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Oct 31, 2026, 10:14 PM EDT
Recruiting Not applicable Interventional

LymphBridge: Surgical Evaluation for Breast Cancer-Associated Lymphedema (BioBridge)

NCT04606030
View directory record Official record
Conditions
Lymphedema, Edema
Interventions
BioBridge® Collagen Matrix, Vascularized Lymph Node Transfer (VLNT)
Device · Procedure
Lead sponsor
Fibralign Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
Chicago, Illinois • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 31, 2026, 10:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Care to Plan: a Tailored Resource for Family Members of Persons With Dementia

NCT03901456
View directory record Official record
Conditions
Dementia, Alzheimer Disease, Memory Loss
Interventions
Care to Plan, Usual Care
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
21 Years and older
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 2, 2023 · Synced Oct 31, 2026, 10:14 PM EDT
Completed Phase 3 Interventional Results available

Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy

NCT03080883
View directory record Official record
Conditions
Cerebral Vein Thrombosis, Deep Vein Thrombosis, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Pulmonary Embolism, Splanchnic Vein Thrombosis
Interventions
Apixaban
Drug
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
32
States / cities
Scottsdale, Arizona • Washington D.C., District of Columbia • Jacksonville, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated May 18, 2025 · Synced Oct 31, 2026, 10:14 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)

NCT05269394
View directory record Official record
Conditions
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
Interventions
E2814, Lecanemab, Matching Placebo (E2814)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
12
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 31, 2026, 10:14 PM EDT
Completed Phase 2 Interventional Results available

A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in People With Depression

NCT04521478
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
BI 1358894, Placebo, Quetiapine
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 65 Years
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
29
States / cities
Birmingham, Alabama • Garden Grove, California • Long Beach, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Oct 31, 2026, 10:14 PM EDT
Not listed Not applicable Interventional

Priming With tDCS: Expanding the Window of Recovery in Chronic Stroke

NCT03964467
View directory record Official record
Conditions
Upper Extremity Paresis
Interventions
transcranial direct current stimulation
Device
Lead sponsor
University of the Sciences in Philadelphia
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 6, 2023 · Synced Oct 31, 2026, 10:14 PM EDT
Not listed Not applicable Interventional

University of Houston Drug Abuse Research Development Program II

NCT03557632
View directory record Official record
Conditions
Heroin Dependence
Interventions
Virtual Reality Cue Exposure Therapy, Relapse Prevention Drug Education
Behavioral
Lead sponsor
University of Houston
Other
Eligibility
18 Years to 64 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Oct 31, 2026, 10:14 PM EDT
Terminated Phase 2 Interventional Results available

Study Evaluating the Safety and Effects of MN-221 in Subjects Experiencing an Acute Exacerbation of Asthma

NCT00683449
View directory record Official record
Conditions
Asthma, Status Asthmaticus
Interventions
Dose Group 1, MN-221 placebo, Dose Group 2, Dose Group 3
Drug
Lead sponsor
MediciNova
Industry
Eligibility
18 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
9
States / cities
Phoenix, Arizona • Los Angeles, California • Sylmar, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2011 · Synced Oct 31, 2026, 10:14 PM EDT
Active, not recruiting Not applicable Interventional

Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes

NCT06267391
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Type2diabetes, Diabetes Mellitus, Type 2, Diabetes, Type 2 Diabetes
Interventions
Endogenex Treatment, Sham Procedure
Device
Lead sponsor
Endogenex, Inc.
Industry
Eligibility
22 Years to 70 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
37
States / cities
Birmingham, Alabama • Gardena, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 31, 2026, 10:14 PM EDT
Recruiting Phase 1 Interventional

Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Limbal Stem Cell Deficiency

NCT06452316
View directory record Official record
Conditions
Limbal Stem Cell Deficiency
Interventions
CSB-001 Ophthalmic Solution 0.1%
Biological
Lead sponsor
Claris Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
6
States / cities
Loma Linda, California • Carmel, Indiana • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 31, 2026, 10:14 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

NCT01386385
View directory record Official record
Conditions
Lung Adenocarcinoma, Lung Adenocarcinoma, Mixed Subtype, Lung Large Cell Carcinoma, Lung Squamous Cell Carcinoma, Minimally Invasive Lung Adenocarcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7
Interventions
3-Dimensional Conformal Radiation Therapy, Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Placebo Administration, Veliparib
Radiation · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
232
States / cities
Anchorage, Alaska • Tucson, Arizona • Beverly Hills, California + 158 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 31, 2026, 10:14 PM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Glutathione vs. Curcumin Clinical Trial

NCT02848417
View directory record Official record
Conditions
Gulf War Syndrome
Interventions
Curcumin, Glutathione, Placebo
Drug · Other
Lead sponsor
South Florida Veterans Affairs Foundation for Research and Education
Federal
Eligibility
35 Years to 70 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 29, 2020 · Synced Oct 31, 2026, 10:14 PM EDT
Completed Not applicable Interventional Results available

Wireless Prosthetic Control Effectiveness Study

NCT06821412
View directory record Official record
Conditions
Prostheses, Upper Limb Amputation Below Elbow
Interventions
ASTERISK System, Wired Configuration
Device
Lead sponsor
Liberating Technologies, Inc.
Industry
Eligibility
18 Years to 89 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Holliston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 31, 2026, 10:14 PM EDT
Terminated Phase 2 Interventional Results available

Testosterone Replacement in Men With Non-Metastatic Castrate Resistant Prostate Cancer

NCT00515112
View directory record Official record
Conditions
Prostate Cancer
Interventions
AndroGel, placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
11
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2014 · Synced Oct 31, 2026, 10:14 PM EDT
Terminated Phase 2 Interventional

Proof-of-concept Study of NSAID Hydrogel Patch in Treatment of Acute Pain

NCT02729207
View directory record Official record
Conditions
Ankle Sprain
Interventions
Esflurbiprofen Hydrogel Patch
Drug
Lead sponsor
Teikoku Seiyaku Co., Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 19, 2021 · Synced Oct 31, 2026, 10:14 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

NCT07215234
View directory record Official record
Conditions
Geographic Atrophy
Interventions
SAR446597, Sham Comparator
Drug
Lead sponsor
Sanofi
Industry
Eligibility
60 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
31
States / cities
Peoria, Arizona • Scottsdale, Arizona • Beverly Hills, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 31, 2026, 10:14 PM EDT